Inhibiting glucocorticoid release, NF-κB nuclear transcription, NLRP3 inflammasome activation and restoring microglial homeostasis in the hippocampus are novel strategies for the development of effective treatments for the management of depression in humans. The gene discussed is NFKB1; the disease is major depressive disorder.